Dear Friends,

There has been a lot of activity at the ECFS since the last edition of our newsletter and here is a brief review of the special projects, what’s new with our society and a few highlights of the upcoming 42nd European Cystic Fibrosis Conference taking place in a few days, this year in Liverpool, United Kingdom.

But first, let me remind you of the **ECFS elections**, which are taking place this month. There are two vacancies at the Board this year. Prof. Margarida Amaral is ending her second term and Prof. Isabelle Sermet finishes her first term and our gratitude goes to both for their contribution to the Board over these last years.

Three candidates applied for these positions as Board members: Trudy Havermans, Claus Moser and Isabelle Sermet.

Your involvement in the ECFS Board Elections is critical and will contribute to shape the future direction of the Society. It is essential that the Board has a strong and engaged membership to provide leadership to our Society. So, if you have not voted yet, please log in and vote [here](#) without delay.

The results of the elections will be announced at the Annual General Meeting (AGM) in Liverpool on Friday 07 June (18:30-19:30, Hall 1C). The AGM is open to all ECFS members and we very much hope that as many of you as possible will attend it. With the elections, the AGM is the moment where members can express their wishes and expectations for the Society. We value your involvement and hope to see more members contribute and input new ideas.
More information on the AGM will appear further down in the newsletter.

The 16th ECFS Diagnostic Network Working Group Meeting took place in Tunis in February, hosted by Samia Hamouda, and all agreed this was a fantastic meeting scientifically and with excellent networking opportunities.

The ECFS Basic Science Conference was held in Croatia this year, 27-30 March 2019. Once again, the conference was a resounding success. We would like to thank the organisers, Isabelle Callebaut (FR), Carlos Farinha (PT) and Martin Mense (US) for putting together a high-quality programme. The abstract book is available on the ECFS website.

We are rapidly approaching our annual conference in Liverpool and the final preparations are well under way. The Scientific Committee has put together an outstanding programme and we have some exciting new basic research and results from clinical trials to discuss. You can find the final programme on the ECFS website. I would like to thank the Scientific Committee and the Steering Committee for all their hard work over the last year in preparing the programme, selecting the abstracts and sorting the various sessions. Besides the conference App featuring the programme and other useful information, other initiatives to note include the Interactive Case studies session, some ‘meet the expert’ sessions organised at lunchtime and open to all, and the ECFS Tomorrow lounge which will feature a series of interesting sessions. We will also continue the CF Innovation Zone that we launched in Belgrade last year, giving the opportunity to health start-ups and innovators to demonstrate their new solutions, applications and technologies.

As part of our commitment to support young researchers, three Young Investigators Awards and 20 travel grants have been awarded to young investigators based on the merit of their abstract submissions. Congratulations to them for their prize!

Please don't miss a visit to the “CF Community” booth area in the Exhibition Hall for information on the various initiatives and programmes. If you are looking for a position or have a job opening to advertise, please send us the information to post on the website and bring an A4 advertisement to the ECFS booth at the conference.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in Cystic Fibrosis contained at the end of this Newsletter.

Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,

Isabelle Fajac
ECFS President
02. ECFS Board Elections - Cast your vote!

The ECFS is holding elections for 2 ECFS Board Members Positions: Margarida Amaral completed her second term and Isabelle Sermet finishes a first tenure. Invitations to take part in the elections have been sent to the ECFS electorate by email. Candidates information and links to supporting documents such as the candidates’ nominations, application letters and CVs are available on the ECFS website. The election deadline is 6 June 2019, 19:30 CEST.

03. ECFS Annual General Meeting @ Liverpool2019

The Annual General Meeting will be held on Friday, 07 June 2019, 18:30-19:30, at the Arena and Convention Centre in Liverpool (Hall 1C).

The Annual General Meeting agenda:
1. President’s Report – Isabelle Fajac
2. Secretary’s Report – Isabelle Sermet
3. Treasurer’s Report – Kevin Southern
4. ECFS Board Elections – Isabelle Sermet
5. Update on Journal of Cystic Fibrosis – Scott Bell
6. CTN Report – Silke van Koningsbruggen-Rietschel
7. ECFS Standards of Care Report – Carlo Castellani
8. ECFS Patient Registry Report – Lutz Nährlich
9. ECFS Education Report – Daniel Peckham
10. ECFS Working Group Reports
   - Antimicrobial Resistance Working Group
   - Basic Science Working Group
   - Diagnostic Network Working Group
   - Exercise Working Group
   - Fungal Pathogens Working Group
   - Mental Health Working Group
   - Neonatal Screening Working Group
   - Pulmonary Exacerbations Working Group
11. ECFS Special Interest Groups
   - Nursing Special Interest Group
   - European CF Pharmacy Group
   - European CF Nutrition Group
   - European Psychosocial Special Interest Group
12. Presentation of the 2020 European CF Conference
13. AOB

We hope to see you!
04. Liverpool Highlights

Like the Beatles used to sing... It won’t be long, it won’t be long ‘till... we meet you in Liverpool!
You can find all the details about the scientific programme here.

A complimentary shuttle service will be offered to a limited number of delegates attending the European Cystic Fibrosis Conference at ACC Liverpool. Delegates arriving at Liverpool John Lennon or Manchester Airport on Tuesday, June 4 and Wednesday, June 5 will be transferred to ACC Liverpool and designated conference hotels.
A return service will be provided on Saturday, June 8 and Sunday, June 9.
All journeys must be booked in advance. This complimentary service is on first come, first served basis.
Please click here to reserve a place and find out more.

Below are some highlights of the conference.
HIGHLIGHTS OF THE CONFERENCE

INTERACTIVE CASE STUDIES
FRIDAY 08:30 - 10:00 / Hall 1B
Live voting will be done through the Conference App.
Install the ECFS 2018 Conference App, click on the Voting Button and enter the room name.
Each interactive case features an evolving patient history and a series of questions designated to test your diagnostic and/or therapeutic skills.
You will receive immediate feedback on your answers and treatment choices, along with the opportunity to compare your final score with those of your peers.

ECFS TOMORROW LOUNGE
The ECFS Tomorrow initiative is geared towards bringing together those who are interested in building their future career in the cystic fibrosis community and the ECFS of tomorrow.

CF INNOVATION ZONE
In this new zone, you will discover start-ups and innovative companies showcasing their exciting new solutions in technology and health. Open your mind to new possibilities and feel inspired!
THURSDAY 10:00 - 10:30
Meet the health tech pioneers in the ePoster Corner C.

MEET THE EXPERT SESSIONS
THURSDAY & FRIDAY 12:45 - 13:45
ePOSTER CORNERS and Room 4B
In these small interactive sessions, you will have the opportunity to ask questions and discuss a specific topic with experts from the field.
The format encourages a more personal approach to learning.
Entrance to the Meet the Experts is free of charge and is on a first come, first served basis! Attendees do not need to book in advance.
05. Liverpool 2019 Conference App

Nearly 70% of the delegates downloaded and used the Conference App in Belgrade last year. Via the app, you are able to view all the information on the scientific programme, the exhibitors, the abstracts and ePosters. The ECFS 2019 Conference App is designed to enhance the experience of the participants before, during and after the Conference. Further information is available on the conference website and the App will soon be ready to download.
06. ECFS Award 2019

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of Cystic Fibrosis or to the treatment or care of patients with Cystic Fibrosis. This year, the ECFS wishes to acknowledge Prof. Stuart Elborn.

Stuart Elborn has for more than two decades been a leading international clinician and scientist in CF. He has also contributed to the ECFS as Board member and President. Stuart was trained in Belfast and helped develop CF centres for adults in Nottingham and Cardiff. When he returned to Belfast in 1995, he started a new adult CF Centre providing care for all adults with cystic fibrosis in Northern Ireland. Besides being director of the Adult CF Centre, he became Professor of Respiratory Medicine at Queen’s University Belfast and later the Dean of Medicine, Dentistry and Biomedical Sciences.

He was Chairman of the Research and Medical advisory committees of the Cystic Fibrosis Trust UK (2002-14) and is now member of its scientific board. After having been elected as a member of the board of the ECFS he served as its President 2007-15, during which he further developed the ECFS to its leading role in International Cystic Fibrosis care, research and education. During his time as President, the ECFS Clinical Trials Network started, and the European Cystic Fibrosis Registry consolidated. As a recognition for Stuart’s service to the health care in Northern Ireland he received the title of Commander of the Order of the British Empire in 2012. In October 2016, Stuart moved to the Royal Brompton and Imperial College in London as centre director and clinical professor of respiratory medicine. He returned to Queen's University Belfast this year to lead the Faculty of Medicine, Health and Life Sciences as Pro-Vice Chancellor and Professor of Medicine. In this role, he is leading a major development in digital health in Northern Ireland as part of a Regional City Deal.

He has made a broad contribution to CF research focused on clinically important CF-topics such as microbiology and host inflammation, anti-bacterial agents, CFTR potentiators, and anti-inflammatory agents. He has led a number of key clinical trials in these areas and is still active in this area. He has also led international guidelines which have improved the standard of care for CF patients. He has supported research in the multidisciplinary team and supervised scientists, medical doctors, physiotherapists and nurses to higher degrees in research. Many of those he has mentored are scientific and clinical leaders in CF and related lung diseases. He has also contributed to research and guideline development in bronchiectasis and leads a major European project in antibiotic treatment in bronchiectasis and CF through the Innovative Medicine Initiative programme in EC Framework 7. Stuart is a strong role model as a clinical academic combining clinical care and research aimed at improving outcomes in people with CF. He passionately champions interdisciplinary person-centred care delivery, driven by data and implemented with respect and compassion.

07. Gerd Döring Award

Professor Gerd Döring was an outstanding leader of the ECFS. During his Presidency the number of members doubled. During this time, he also initiated a highly successful annual conference on basic science and consensus conferences on the treatment of lung infection, early intervention and prevention of lung disease, drug inhalation and related devices, nutrition, along with recommendations for several clinical trials in Cystic Fibrosis, which have had a significant impact on treatment.
The support of young investigators was a high priority for him and to honour his enormous contribution, the ECFS has initiated a Gerd Döring Award that will be given annually to honour an exceptional early career young European scientist. The award is primarily judged on a paper published in the previous 3 calendar years, which has made a significant impact on the understanding or treatment of Cystic Fibrosis. This year, the Gerd Döring Award has been granted to Dr. Elvira Sondo, in acknowledgement of her recent remarkable contribution to Cystic Fibrosis. The Award, which includes a monetary grant of 5,000 Euro to support research, will be presented during the Opening Plenary of the Liverpool Conference.

In 2005, after graduating with honors in Biological Sciences at the University Federico II of Naples, Elvira Sondo joined the UOC Genetica Medica of Istituto Giannina Gaslini in Genoa, Italy. At the time, she was actively involved in a scientific project coordinated by Prof. Luis Galietta, that led to the molecular identification of the long-sought alternative calcium-dependent Cl- channel TMEM16A, published in 2008 in Science. Moreover, the study of the structure / function relationship of the TMEM16A protein and the role of the other anoctamines belonging to the TMEM16 family was the topic of her doctoral project obtained at the University of Genoa in 2016.

More recently she was enrolled as a fellow in several projects funded by the Italian Cystic Fibrosis Foundation coordinated by Dr. Nicoletta Pedemonte aimed at the identification of novel therapeutic strategies for cystic fibrosis (CF). In particular, Elvira focused her attention on CFTR pharmacology with several publications reporting the identification of CFTR correctors and potentiators by high-throughput methods and their evaluation in native epithelial cells.

In 2018 Elvira first-authored a paper reporting the discovery of the first pharmacological modulator of the ubiquitin ligase RNF5. Indeed, previous works demonstrated that genetic suppression of RNF5 in vivo leads to an attenuation of intestinal pathological phenotypes in CF mice. Elvira used a computational approach to discover inh-02, a drug-like small molecule that inhibits RNF5 and is able to rescue F508del-CFTR processing defect in primary bronchial epithelial cells from patients with CF. This work validates RNF5 as a drug target for CF, providing evidence to support its druggability. RNF5 inhibition in patients with CF and chronic lung infection could also have secondary beneficial effects, since RNF5 regulation of autophagy is involved in the innate host defense against bacterial infection.

This year Elvira has also been the recipient of a Young Investigator Grant from the Italian Ministry of Health.

Elvira will present her research at the conference in Liverpool, in the Late Breaking Science Session scheduled on Friday, June 7, 17:00 – 18:30 in Hall 1C.
Education is one of the major objectives for the ECFS. Several courses will be organised prior to the conference:

- Acceptance and Commitment Therapy for Cystic Fibrosis: an introduction- Tuesday 04 June 2019 - 09:00 - 17:00
- Physiotherapy Short Course - Exercise Testing in Cystic Fibrosis - Who, When and Why? - Tuesday 04, 08:00 - 17:30 and Wednesday 05 June 2019, 08:30-12:00
- Nutrition Advanced Course – Scrutinizing the future for Nutrition in Cystic Fibrosis - Tuesday 04 June 2019 - 12:30 - 17:00
- An Introductory Course, for all team members, in Cognitive Behavioral Therapy and Interpersonal Therapy - Wednesday 05 June 2019 - 09:00 - 17:00

More information about these courses can be found [here](#)
We see the ECFS Tomorrow as a means to improve one of the fundamental objectives of the Society – to support and engage young scientists working in the field of Cystic Fibrosis. It is essential to provide professionals who are new to the community with opportunities to connect in a meaningful way with current leaders and experts. In turn, the new generation of specialists bring up-to-date approaches and practices to the wealth of experience that already exists within the society’s ranks.

Located adjacent to the Exhibition Area of the conference venue, the ECFS Tomorrow Lounge will feature interactive workshops organised by the ECFS Special Interest Groups on Thursday and Friday. Come and take an active part in the debate and discussions on different aspects of cystic fibrosis management and care.

<table>
<thead>
<tr>
<th>WEDNESDAY, JUNE 5</th>
<th>FRIDAY, JUNE 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>20:00 – 21:00</td>
<td>Meet &amp; Greet</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THURSDAY, JUNE 6</th>
<th>FRIDAY, JUNE 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 13:45</td>
<td>The changing picture of nutritional management in cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Sejal Pandya, Liverpool, UK / Clare Woodland, Liverpool, UK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SATURDAY, JUNE 8</th>
<th>FRIDAY, JUNE 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:00</td>
<td>Farewell coffee</td>
</tr>
</tbody>
</table>

12:45 – 13:45 Mental Health in my hospital: tools to start screening and how to move on
Urszula Borawska-Kowalczyk, Warsaw, PL / Anna Georgioupoilos, Boston, US / Annette Katscher-Peitz, Stuttgart, DE / Yvonne Prins, Amsterdam, NL / Marieke Verkleij, Amsterdam, NL

14:00 – 15:00 How do we cope with new cases of MTB?
Majda Oštir, Ljubljana, SI

17:00 – 18:00 Working with parents of children/adolescents with CF and the child with CF
Sue Braun, Brussels, BE / Angelique Tijtgat, Brussels, BE
## 10. Meetings in Liverpool

### Tuesday 4 June 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 17:00</td>
<td>ECFS Board Meeting*</td>
</tr>
<tr>
<td>08:30 - 17:30</td>
<td>Physiotherapy Short Course - Exercise Testing in Cystic Fibrosis – Who, When And Why?**</td>
</tr>
<tr>
<td>09:00 – 17:00</td>
<td>Acceptance and Commitment Therapy for Cystic Fibrosis; an introduction**</td>
</tr>
<tr>
<td>12:30 - 17:00</td>
<td>Nutrition Advanced Course – Scrutinizing the future for Nutrition in Cystic Fibrosis**</td>
</tr>
</tbody>
</table>

### Wednesday 5 June 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 12:00</td>
<td>Physiotherapy Short Course – Exercise Testing in Cystic Fibrosis – Who, When And Why?**</td>
</tr>
<tr>
<td>08:30 – 12:45</td>
<td>ECFS CTN Training and Development*</td>
</tr>
<tr>
<td>08:30 – 16:00</td>
<td>ECFS Nursing Special Interest Group Meeting**</td>
</tr>
<tr>
<td>09:00 – 16:30</td>
<td>European Cystic Fibrosis Nutrition Group Meeting**</td>
</tr>
<tr>
<td>09:00 – 17:00</td>
<td>An Introductory Course, for all team members, in Cognitive Behavioral Therapy and Interpersonal Therapy**</td>
</tr>
<tr>
<td>09:30 – 15:00</td>
<td>ECFS Neonatal Screening Working Group Meeting</td>
</tr>
<tr>
<td>09:30 – 16:45</td>
<td>European Psychosocial Special Interest Group (EPSIG) Meeting**</td>
</tr>
<tr>
<td>10:00 – 16:00</td>
<td>European Cystic Fibrosis Pharmacy Group Meeting</td>
</tr>
<tr>
<td>10:00 – 12:30</td>
<td>CFHealthHub: learning health system and improvement collaborative. From rescue to prevention using a digital adherence platform</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>ECFS Patient Registry Executive Committee Meeting*</td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>International Physiotherapy Group for Cystic Fibrosis (IPG/CF) Annual General Meeting</td>
</tr>
<tr>
<td>12:45 – 17:30</td>
<td>ECFS CTN Training Research Coordinators*</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>ECFS International (Global) Cystic Fibrosis Registry Group*</td>
</tr>
<tr>
<td>13:00 – 17:00</td>
<td>CFHealthHub: improvement collaborative data orientation and micro systems improvement training*</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>13:15 – 18:20</td>
<td>ECFS CTN Steering Committee Meeting*</td>
</tr>
<tr>
<td>14:00 – 17:00</td>
<td>ECFS Exercise Working Group Meeting*</td>
</tr>
<tr>
<td>14:30 – 17:00</td>
<td>Physiotherapy Case Presentations</td>
</tr>
<tr>
<td>14:45 – 16:00</td>
<td>ECFSPR Scientific Committee Meeting*</td>
</tr>
<tr>
<td>15:00 – 17:00</td>
<td>ECFS DNWG Sweat testing workshop</td>
</tr>
<tr>
<td>15:00 – 17:00</td>
<td>IJNS supplement team meeting*</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>ECFS Fungal Pathogens Working Group Meeting</td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td>MedDRA coding training</td>
</tr>
<tr>
<td>17:00 – 18:00</td>
<td>ECFS Patient Registry Software Training</td>
</tr>
<tr>
<td>17:00 – 18:30</td>
<td>Global CF*</td>
</tr>
<tr>
<td>17:00 – 18:30</td>
<td>IPG/CF Board Meeting*</td>
</tr>
</tbody>
</table>

**Thursday 6 June 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:30</td>
<td>Journal of Cystic Fibrosis (JCF) Editorial Board Meeting*</td>
</tr>
<tr>
<td>12:00 – 14:00</td>
<td>UKCFMA Meeting*</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>European Registry Data Quality Project Group Meeting*</td>
</tr>
<tr>
<td>12:30 – 14:30</td>
<td>ECFS CTN Standardisation Committee Meeting*</td>
</tr>
<tr>
<td>12:30 – 14:30</td>
<td>ECFS Standards of Care Group Meeting*</td>
</tr>
<tr>
<td>13:30 – 14:30</td>
<td>ECFS Patient Registry – Meeting for Interested Parties</td>
</tr>
<tr>
<td>15:30 – 17:30</td>
<td>CFTR2 project*</td>
</tr>
<tr>
<td>16:30 – 17:30</td>
<td>CF Europe Joint Project Meeting</td>
</tr>
<tr>
<td>18:00 – 19:00</td>
<td>ECFS Patient Registry Software Training</td>
</tr>
<tr>
<td>18:30 – 20:00</td>
<td>ECFS CTN Inflammatory Biomarkers Meeting</td>
</tr>
<tr>
<td>18:30 – 20:00</td>
<td>ECFS Education Committee Meeting*</td>
</tr>
<tr>
<td>18:30 – 20:30</td>
<td>ECFS Pulmonary Exacerbation Working Group Meeting*</td>
</tr>
</tbody>
</table>
### Friday 7 June 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 – 08:15</td>
<td>National Institute of Health Research funding call information meeting for UK medical and allied health researchers</td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>ECFS Mental Health Working Group Meeting*</td>
</tr>
<tr>
<td>12:00 – 14:00</td>
<td>ECFS CTN Lung Clearance Index Workshop*</td>
</tr>
<tr>
<td>12:30 – 14:30</td>
<td>ECFS Diagnostic Network Working Group Meeting</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>CF START Trial Investigators Meeting*</td>
</tr>
<tr>
<td>12:30 – 14:30</td>
<td>ECFS Patient Registry Steering Group Meeting*</td>
</tr>
<tr>
<td>15:00 – 16:00</td>
<td>ECFS Patient Registry Software Training</td>
</tr>
<tr>
<td>18:30 – 19:30</td>
<td>ECFS Annual General Meeting* – ECFS members only</td>
</tr>
</tbody>
</table>

### Saturday 8 June 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 17:00</td>
<td>Cystic Fibrosis Trust &amp; CF Europe Community event</td>
</tr>
<tr>
<td>13:30 – 18:00</td>
<td>ECFS Scientific Committee Meeting – Lyon 2020*</td>
</tr>
</tbody>
</table>

* By invitation only
** Extra registration needed
11. 2019 ECFS Basic Science Conference - Dubrovnik, Croatia

The ECFS Basic Science Conference was held in Dubrovnik, Croatia between 27 and 30 March 2019. With nearly 200 participants, the conference was a resounding success. We would like to thank the organisers, Isabelle Callebaut (FR), Carlos Farinha (PT) and Martin Mense (US) for putting together a high-quality programme. The abstract book is available on the ECFS website.

12. ECFS Basic Science WG Workshop

The ECFS Basic Science Working Group will organise its 4th workshop in Lisbon, Portugal on 22 – 26 July 2019.

Free registration - Some travel grants are available.
To apply, please send a CV, letter of motivation and recommendation letter to ESP2019@fc.ul.pt
Application deadline: 31 May 2019
More information here

13. Education Platform

Each month we post a ‘Highlight of the month’ feature which includes relevant talks and material on a particular topic.

The topic for May 2019 is ‘CF Diagnosis’ and brings together symposia from the ECFS conferences in Belgrade (2018) and Seville (2017), and one presentation (both available in English and Spanish) from ‘The Essential Toolkit’ course.

14. Upcoming Events

- ECFS Board Meeting 05 June 2019, Liverpool, UK
- ECFS Annual General Assembly - 07 June 2019 – Liverpool, UK
- **42nd European CF Conference** – 05-08 June 2019 – Liverpool, UK
- **Summer School on epithelial systems: physiology and pathophysiology**, 22-26 July 2019 – Lisbon, Portugal
- **Scientific Meeting organised by Mukoviszidose e.V.**, 19-20 September 2019 - Schloss Montabaur, Germany
- **2019 European Respiratory Society Congress** 28 September – 02 October 2019 – Madrid, Spain
- **North American CF Conference**, 31 October – 02 November 2019, Nashville, TN, United States
- **43rd European CF Conference** – 03-06 June 2020, Lyon, France

**15.Current References in Cystic Fibrosis**

Please go to next page.
Antimicrobials

Intracellular localization of polymyxins in human alveolar epithelial cells
*Journal of Antimicrobial Chemotherapy* 2019; 74: 48 - 57

Ahmed SAKS., Rudden M., Smyth TJ., Dooley JSG., Marchant R., Banat IM.
Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors
*Applied Microbiology and Biotechnology* 2019; 103: 3521 - 3535

Four Decades of beta-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis
*Clinical Pharmacokinetics* 2019; 58: 143 - 156

Cafora M., Dellflorian G., Forli F., Ferrari L., Binelli G., Briani F., Ghisotti D., Pistocchi A.
Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model
*Scientific Reports* 2019; 9: ArNo: 1527

Chang RYK., Das T., Manos J., Kutter E., Morales S., Chan HK.
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients
*AAPS Journal* 2019; 21: 3: UNSP 49

Chen QQ., Shah KN., Zhang FW., Salazar AJ., Shah PN., Li RC., Sacchettini JC., Wooley KL., Cannon CL.
Minocycline and Silver Dual-Loaded Polyphosphoester-Based Nanoparticles for Treatment of Resistant Pseudomonas aeruginosa Molecular Pharmacueticals 2019; 16: 1606 - 1619

Cho DY., Lim DJ., Mackey C., Weeks CG., Garcia JAP., Skinner D., Zhang S., McCormick J., Woodworth BA.
In-vitro evaluation of a ciprofloxacin- and ivaflacof-coated sinus stent against Pseudomonas aeruginosa biofilms
*International Forum of Allergy & Rhinology* 2019; 9: 486 - 492

Clark ST., Sinha U., Zhang Y., Wang PW., Donaldson SI...
Coburn B., Waters VJ., Yau YCW., Tullis DE., Gutman DS., Hung DM.
Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with beta-lactams
*International Journal of Antimicrobial Agents* 2019; 53: 620 - 628

Cras RL., Pai MP., Lodise TP.
Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can troughymycin measurements help?
*Journal of Antimicrobial Chemotherapy* 2019; 74: 126 - 129

Cui CY., Song SH., Yang CX., Sun XY., Huang YT., Li K., Zhao S., Zhang YL., Deng YY.
Disruption of Quorum Sensing and Virulence in Burkholderia cenocepacia by a Structural Analogue of the cis-2-Dodecenic Acid Signal
*Applied and Environmental Microbiology* 2019; 85: e00739-18

Dolce D., Neri S., Grisotto L., Landersdorfer CB.
Defective FNR-FGFL5 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol
*American Journal of Physiology-Gastrointestinal and Liver Physiology* 2019; 316: G404 - G411

Donnelley M., Morgan KS., Gradl R., Klein M., Hausermann D., Hall C., Maksmenko A., Parsons DW.
Defective exocytosis and processing of insulin in a cystic fibrosis mouse model
*Journal of Endocrinology* 2019; 241: 45 - 57

In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis
*Science Translational Medicine* 2019; 11: 485:eaau7531

Gunay N., Akar F., Gokbulut C., Sakarya S. Determination of the Differences in Penetration of Tetracycline and Vancomycin into Bronchial Epithelium of Normal and Cystic Fibrosis Lung Klinik Journal 2018; 31: 139 - 143


Hubble VB., Hubbard BA., Minrovic BM., Melander RJ., Melander C. Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa ACS Infectious Diseases 2019; 5: 141 - 151


Jaggupilli A., Singh N., De Jesus VC., Gounni MS., Dhanaraj P., Chellikani P. Chemosensory bitter taste receptors (T2Rs) are activated by multiple antibiotics FASEB Journal 2019; 33: 501 - 517


Kuilova V., Chernukha MV., Morozova EA., Revtovich SV., Rodionov AN., Koval VS., Avelisyan LR., Kullastova DG., Shagina IA., Demidkina TV. Antibacterial Effect of Thiosulfonates on Multiresistant Strains of Bacteria Isolated from Patients with Cystic Fibrosis Acta Naturae 2018; 10: 77 - 80

Le Run E., Arthur M., Mainardi JL. In Vitro and Intracellular Activity of Imipenem Combined with Tetracyclol, Rifabutin, and Avibactam against Mycobacterium abscessus Antimicrobial Agents and Chemotherapy 2019; 63: e01915-18

Maiden MM., Zachos MP., Waters CM. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential Journal of Antimicrobial Chemotherapy 2019; 74: 894 - 906

Massip C., Mathieu C., Gaudru C., Miatu V., Floch P., Oswald E., Segonds C., Guet-Revillet H. In vitro activity of seven beta-lactams including cefotaxime/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients Journal of Antimicrobial Chemotherapy 2019; 74: 525 - 528


Robert AEL., Powell I.C., Pritchard MF., Thomas DW., Jennings RE. Anti-pseudomonal Activity of Manuka Honey and Antibiotics in a Specialized ex vivo Model Simulating Cystic Fibrosis Lung Infection Frontiers in Microbiology 2019; 10: ArNo: 869


Van Stormbreck B., Zampoli M., Morrow BM. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis Pediatric Pulmonology 2019; 54: 393 - 398

Cardiology

Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine 2019; 199: 987 - 995

Schapkaiz E., Weil R., White D., Klugman S.
Asymptomatic catheter-related venous thrombosis in a child with cystic fibrosis: When to treat?
Journal of Vascular Nursing 2019; 37: 43 – 45

Cell Biology

Chioccioli M., Feriani L., Kotar J., Bratcher P.E., Cicuta P.
Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis epithelial cells
Nature Communications 2019; 10: ArNo: 1763

Dutta RK., Chinnapaiyan S., Rasmussen L., Raju SV., Unwalla H.L.
A Neutralizing Aptamer to TGFBR2 and miR-145 Antagonism Rescue Cigarette Smoke- and TGF-beta-Mediated CFTR Expression Molecular Therapy 2019; 27: 442 - 455

Faraj J., Bodas M., Pehote G., Swanson D., Sharma A., Vij N.
Novel cystamine-core dendrimer-formulation rescues Delta F508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy

Jennings S., Ng HP., Wang GS.
Establishment of a Delta F508 CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy
Biomedical & Pharmacotherapy 2019; 111: 1249

Kunzelmann K., Ousingsawat J., Pinto L., Leria Jr., Wanitchakool P., Schreiber R., Kunzelmann K.
Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR
Journal of Molecular Medicine-jmm 2019; 97: 711 - 722

CFTR Protects against Mycobacterium abscessus Infection by Fine-Tuning Host Oxidative Defenses
Cell Reports 2019; 26: 1828 - 1842

Chen X.Y., Zhu SY., Zhenin M., Xu WY., Bose SJ., Wong MPF., Leung GPL., Senderowitz H., Chen J.H.
A defective flexible loop contributes to the processing and gating defects of the predominant cystic fibrosis-causing mutation
FASEB Journal 2019; 33: 5126 - 5142

Chiu WT., Tran TTV., Pan SC., Huang HK., Chen YC., Wong TW.
Cystic Fibrosis Transmembrane Conductance Regulator: A Possible New Target for Photodynamic Therapy Enhances Wound Healing Advances in Wound Care 2019; 10: ArNo: 252

Csanady L., Vergani P., Gadsby DC.
Structure, gating, and regulation of the CFTR anion channel
Physiological Reviews 2019; 99: 707 - 738

Douiran J.E., Le CA., Ody BK., Bruce JB., Post SJ., Thacker NL., Hill HM., Breton GW., Mulder MJ., Chang S.C., Bridges TM., Tang LP., Wang W., Rowe SM., Aller SC., Turlington M.
Evaluation of 1,2,3-Triazoles as Amide Biososteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809
Chemistry-A European Journal 2019; 25: 3662 - 3674

Garcia-Mendiola T., Elosegui CG., Bravo I., Pariente F., Jacobo-Martín A., Navío C., Rodriguez I., Wannemacher R., Lorenzo E.
Fluorescent C-NanoDots for rapid detection of BRCA1, CFTR and MRP3 gene mutations
Microchimica Acta 2019: 186

Gifford AH., Heltsle SL., Goss CH.
CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis

Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation
Molecular Biology of the Cell 2019; 30: 4 - 16

Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation
Molecular Biology of the Cell 2019; 30: 4 - 16

Kittayaruksakul S., Sawasvirojwong S., Noitern R., Pongkorpsakol P., Muapersat C., Chatsudthipong V.
Activation of constitutive androstane receptor inhibits intestinal CFTR-mediated chloride transport
Biomedicine & Pharmacotherapy 2019; 111: 1249 - 1259

Kramer G., Treff A., Hartmann A., Stone TA., Schenkel M., Keller S., Deber CM., Schlierf M.
A minimal helical-harpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR
Communications Biology 2018; 88: 3-UNSP 981

Li P., Singh J., Sun YF., Ma X., Yuan P.
CFTR constrains the differentiation from mouse embryonic stem cells to intestine lineage cells
Biological and Biochemical Research Communications 2019; 510: 322 - 328

CFTR

Awatade NT., Ramalho S., Silva IAL., Felicio V., Botelho HM., de Poel E., Vonk A., Beekman JM., Farinha CM., Amaral MD.
R560S: A class II CFTR mutation that is not rescued by current modulators
Journal of Cystic Fibrosis 2019; 18: 182 - 189

Barnaby R., Koepfen K., Stanton BA.
Cyclodextrins reduce the ability of Pseudomonas aeruginosa outer-membrane vesicles to reduce CFTR Cl- secretion

Different immunohistochemical localization for TMEM16A and CFTR in acinar and ductal cells of rat major salivary glands and exocrine pancreas
Acta Histochemica 2019; 121: 50 - 55

Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux
Cell Death & Disease 2019; 10: ArNo: 242
Epidemiology

Hinds DM, Sanders DB, Slaven JE, Romero M, Davis SD, Stevens JC.
Cystic fibrosis in El Salvador
Pediatric Pulmonology 2019; 54: 369 - 371

Genotypic characterization of Pseudomonas aeruginosa isolates from Turkish children with cystic fibrosis
Infection and Drug Resistance 2019; 12: 675 - 685

Prevalence of Cystic Fibrosis Trans-membrane Conductance Regulator Gene common mutations in children with cystic fibrosis in Isfahan, Iran

Exercise

Causer AJ, Shute JK, Cummings MH, Shepherd AL, Bright V, Connett G, Allenby ML, Carroll MP, Daniels T, Saynor ZL.
Supramax exercise testing in cystic fibrosis: not ready for prime time
Reply
Journal of Applied Physiology 2019; 126: 265

Cooper DM.
Supramax exercise testing in cystic fibrosis: not ready for prime time
Journal of Applied Physiology 2019; 126: 264

Cox NS, Pepin V, Holland AE.
Greater Sleep Fragmentation Is Associated With Less Physical Activity in Adults With Cystic Fibrosis
Journal of Cardiopulmonary Rehabilitation and Prevention 2019; 39: E11 - E14

Parazzi PLF, Marson FAL, Ribeiro MAGO, Schivinski CIS, Ribeiro JD.
Evaluation of respiratory dynamics by volumetric capnography during submaximal exercise protocol o six minutes on treadmill in cystic fibrosis patients
Jornal de Pediatria 2019; 95: 76 - 86

Exercise testing in patients with cystic fibrosis: importance of ventilatory parameters
European Journal of Applied Physiology 2019; 119: 227 - 234

Ward N, Stillier K, Holland AE.
Exercise as a therapeutic intervention for people with cystic fibrosis

Williams CA, Wedgwood KCA, Mohammad H, Prouse K, Tomlinson OW, Tsaneva-Atanasova K.
Cardiopulmonary responses to maximal aerobic exercise in patients with cystic fibrosis
PLoS One 2019; 14: 2:e0211219

Wu K, Mathur S.
Clinical Usefulness of Functional Tests of Leg Muscle Strength and Power in Adults With Cystic Fibrosis
Respiratory Care 2019; 64: 240 – 241

Gastroenterology

Severe ileocolic inflammatory syndrome in adult patients with cystic fibrosis
Zeitschrift Fur Gastroenterologie 2019; 57: 312 - 316

Psychometric evaluation of a patient-reported outcome measure in pancreatic exocrine insufficiency (PEI)
Pancreatology 2019; 19: 182 – 190

General Review

[Anonymous].
The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis: Verona, Italy. 22-24 November 2018
Multidisciplinary Respiratory Medicine 2019; 14:

Bono-Neri F, Romano C, Isede A.
Cystic Fibrosis: Advancing Along the Continuum
Journal of Pediatric Health Care 2019; 33: 242 - 254

Goetz D, Ren CL.
Review of Cystic Fibrosis
Pediatric Annals 2019; 48: E154 - E161

Gene Therapy

Self-assembled peptide-poxvaccine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis
Nature Nanotechnology 2019; 14: 287

Loza LI M, Yuen EC, Mccray PB.
Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Genes 2019; 10: 3:218

Qaisar F, Habib A, Riaz M, Rehman ZU.
Barriers and recent advances in non-viral vectors targeting the lungs for cystic fibrosis gene therapy
Nanomedicine Journal 2019; 6: 75 - 84

Xia E, Zhang YQ, Cao HB, Li J, Duan RQ, Hu J.

Genetics

Chhed A, Dama T, Goradia D, Pande S, Vinarkar S.
Fetal and Pediatric Pathology 2018; 37: 448 - 451

AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations
Journal of Cystic Fibrosis 2019; 18: 127 - 134

Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci
PloS Genetics 2019; 15: 2:e1008007

Keenan K, Dupuis A, Griffin K, Castellani C, Tullis E, Gonska T.
Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His
Journal of Cystic Fibrosis 2019; 18: 265 - 270
Kurbel S.
Was the Last Ice Age dusty climate instrumental in spreading of the three "Celtic" diseases (hemochromatosis, cystic fibrosis and palmar lipomatosis)?

*Medical Hypotheses* 2019; 122: 134 - 138

Pereira VN, Ribeiro JD, Ribeiro AF, Bertuzzo CS, Marson FA.
Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools

*Scientific Reports* 2019; 9: ArNo: 6234

Spectrum of CFTR mutations in Cevene cystic fibrosis patients: high frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G > A (p.Glu92Lys, E92K) mutations in North Caucasus

*BMC Medical Genetics* 2019; 20: ArNo: 44

Petrova NV, Marakhonov AV, Vasilevya TA, Kashirskaya NYA, Ginter EK, Kutsev SL, Zinchenco RA.
Comprehensive genotyping reveals novel CFTR variants in cystic fibrosis patients from the Russian Federation

*Clinical Genetics* 2019; 95: 444 - 447

Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing

*Gene* 2019; 696: 28 - 32

Schucht S, Minson R, Lex C, Reis J, Stanke F, Tamms S, van Barneveld A, Tummler B.
Functional analysis of the [p.Arg74Trp;Val201Met;Asp1270Asn]/p.Phe508del CFTR mutation

*Gene* 2019; 696: 28 - 32

Wakabayashi-Nakao K, Yu YC, Nakakuki M, Hwang TC, Ishigou H, Sohna Y.
Characterization of (G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients


Growth & Development

Gruet M, Saynor Z.
Assessment of Peripheral Muscle Function in Cystic Fibrosis: Why and How?

*Respiratory Care* 2019; 64: 238 - 240

Robinson CA, Hofer M, Benden C, Schmid C.
Evaluation of bone disease in cystic fibrosis patients from the Russian Federation

*Clinical Genetics* 2019; 95: 444 - 447

Petrova NV, Marakhonov AV, Vasilevya TA, Kashirskaya NYA, Ginter EK, Kutsev SL, Zinchenco RA.
Comprehensive genotyping reveals novel CFTR variants in cystic fibrosis patients from the Russian Federation

*Clinical Genetics* 2019; 95: 444 - 447

Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing

*Gene* 2019; 696: 28 - 32

Schucht S, Minson R, Lex C, Reis J, Stanke F, Tamms S, van Barneveld A, Tummler B.
Functional analysis of the [p.Arg74Trp;Val201Met;Asp1270Asn]/p.Phe508del CFTR mutation

*Gene* 2019; 696: 28 - 32

Wakabayashi-Nakao K, Yu YC, Nakakuki M, Hwang TC, Ishigou H, Sohna Y.
Characterization of (G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients


Immunology & Inflammation

Balakrishnan A, Karki R, Berwin B, Yamamoto M, Kanneganti TD.
Guanylate binding proteins facilitate caspase-11-dependent pyroptosis in response to type 3 secretion system-negative Pseudomonas aeruginosa

*Cell Death Discovery* 2018; 24: 5164 - 5174

Bezzerri V, Placenza F, Caporelli N, Malavolta M, Provinciali M, Cipollì M.
Is cellular senescence involved in cystic fibrosis?

*Respiratory Research* 2019; 20: ArNo: 32

Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrous Bronchial Epithelial Cells

*Biological & Pharmaceutical Bulletin* 2019; 42: 489 - 495

A randomised trial of vitamin D in acute-stage allergic bronchopulmonary aspergillosis complicating asthma

*Mycoses* 2019; 62: 320 - 327

Eyuboglu TS, Aslan AT, Gursoy TR, Onay ZR, Kocak U, Tapişiz AA.
Macrophage activation syndrome due to Nocardia spp in a pediatric patient with cystic fibrosis

*Pediatric Pulmonology* 2019; 54: E10 - E12

Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function

*Journal of Cystic Fibrosis* 2019; 18: 64 - 70

Jiang KY, Poppenberg KE, Wong LP, Chen YM, Borowitz D, Goetz D, Sheehan D, Frederick C, Tutino VM, Meng H, Jarvis JN.
RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations

*Journal of Cystic Fibrosis* 2019; 18: 194 - 202

Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis


Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis


Mauch RM, Rossi CL, da Silva MTN, Aiello TB, Ribeiro JD, Ribeiro AF, Hoiby N, Levy CE.
Detecting Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients

*Medical Microbiology and Immunology* 2019; 208: 205 - 213

Montaz Ali, Lambrecht BN, Naranjo JR, Schock BC.
Regulators of A20 (TNFAIP3): new drug-able targets in inflammation


Mulcahy ELM, Cooley MA, McGuire H, Asad S, de St Groth BF, Beggs SA, Roddam LF.
Widespread alterations in the peripheral blood innate immune cell profile in cystic fibrosis reflect lung pathology

*Immunology and Cell Biology* 2019; 97: 416 - 426

Muraglia KA, Chorghade RS, Kim BR, Tang XX, Shah VS, Grillo AS, Daniels PN, Cioffi AG, Karp PH, Zhu LY, Welsh MJ, Burke MD.
Small-molecule ion channels increase host defences in cystic fibrosis

*Journal of Cystic Fibrosis* 2019; 18: 194 - 202

Olszowiec-Chlebna M, Koniarek-Maniecka A, Brzozowska A, Blauza A, Rychlik B, Stelmach I.
Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa- pilot study

*Italian Journal of Pediatrics* 2019; 45: ArNo: 41


Ramirez AM., Iribarren ME., Moreno BB., Giron RM. Clinical Deterioration Due to Exophiala Dermatitidis in a Patient with Cystic Fibrosis. *Archivos de Bronconeumología* 2019; 55: 162 - 163


Vasireddy R., Veduredy S., Brown-Elliott BA., Greninger AL., Davidson RM., Ard KL., Turenne CV., Wallace RJ. Mycobacterium talmoniae, a Potential Pulmonary Pathogen Isolated from Multiple Patients with Bronchiectasis in the United States, including the First Case of Clinical Disease in a Patient with Cystic Fibrosis. *Journal of Clinical Microbiology* 2019; 57: 2:UNSP e00906-
Physiotherapy

Lang RL., Wilson C., Stockton K., Russell T., Johnston LM. 
CyFiT telehealth: protocol for a randomised controlled trial of an online outpatient physiotherapy service for children with cystic fibrosis 
BMC Pulmonary Medicine 2019; 19: ArNo: 21

O'Sullivan KJ., Collins L., McGrath D., Linnane B., O'Sullivan L., Dunne CP. 
Oscillating Positive Expiratory Pressure Therapy May Be Performed Poorly by Children With Cystic Fibrosis 
Respiratory Care 2019; 64: 398 - 405

Wilson LM., Morrison L., Robinson KA. 
Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews 
Cochrane Database of Systematic Reviews 2019; : 1:CD011231

Zeren M., Cakir E., Gurses IN. 
Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial 
Respiratory Medicine 2019; 148: 24 – 30

Psychosocial

Abbott J., Havermans T., Jarvholm S., Landau E., Prins Y., Smrekar U., Staab D., Verity L., Verkleij M. 
Mental Health screening in cystic fibrosis centres across Europe 
Journal of Cystic Fibrosis 2019; 18: 299 - 303

Arden MA., Drabble S., O'Cathead A., Hutchings M., Wildman M. 
Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework 
British Journal of Health Psychology 2019; 24: 357 - 380

Cronly J., Duff AJ., Riekert K., Horgan A., Lehane E., Perry IJ., Fitzgerald A., Howe B., Chroinin MN., Savage E. 
Positive mental health and wellbeing in adults with cystic fibrosis: A cross sectional study 

Cronly JA., Duff AJ., Riekert KA., Fitzgerald AP., Perry IJ., Lehane EA., Horgan A., Howe BA., Chroinin MN., Savage E. 
Health-Related Quality of Life in Adolescents and Adults With Cystic Fibrosis: Physical and Mental Health Predictors 
Respiratory Care 2019; 64: 406 - 415

Cronly J., Horgan AM., Lehane E., Howe B., Duff AJ., Riekert KA., Perry IJ., Fitzgerald AP., Chroinin MN., Savage E. 
Anxiety and Depression in Parent Caregivers of Children with Cystic Fibrosis 

Cronly J., Savage E. 
Positive mental health and wellbeing in adolescents with cystic fibrosis 

Foil KE., Powers A., Raraigh KS., Wallis K., Southern KW., Salinas D. 
The increasing challenge of genetic counseling for cystic fibrosis 
Journal of Cystic Fibrosis 2019; 18: 167 - 174

Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study 
BMC Pulmonary Medicine 2019; 19: ArNo: 77

Hoo ZH., Wildman MJ., Campbell MJ., Walters SJ., Gardner B. 
A pragmatic behavior-based habit index for adherence to nebulized treatments among adults with cystic fibrosis 
Patient Preference and Adherence 2019; 13: 283 - 294

Hosseinzadeh SS., Rafeev M., Vahedi L., Noorazar SG. 
The Frequency of Psychiatric Disorders in Cystic Fibrosis Patients Aged 5-18 Years in Northwest of Iran 
Crescent Journal of Medical and Biological Sciences 2019; 6: 56 - 60

Maras D., Balfour L., Tosca GA., Gaudet E., Aaron SD., Cameron WD., Pakhale S. 
Breathlessness catastrophizing relates to poorer quality of life in adults with cystic fibrosis 
Journal of Cystic Fibrosis 2019; 18: 150 - 157

Oates GR., Stepanikova I., Rowe SM., Gamble S., Gutierrez HH., Harris WT. 
Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis 
Respiratory Care 2019; 64: 176 - 181

Saxby N., Beggs S., Battersby M., Lawn S. 
What are the components of effective chronic condition self-management education interventions for children with asthma, cystic fibrosis, and diabetes? A systematic review 

Tomaszek L., Debeka G., Cepuch G., Kulpa M., Pawlik L., Broniatowska E. 
Evaluation of quality of life predictors in adolescents and young adults with cystic fibrosis 
Heart & Lung 2019; 48: 159 - 165

Assessment of Sexual Reproductive Health Knowledge Amongst Patients with Cystic Fibrosis 
Sexuality and Disability 2019; 37: 15 – 23

Pulmonology

Bell SC., Stuart RL. 
Infection risks for patients from healthcare workers with cystic fibrosis 
Respirology 2019; 24: 393 - 394

Bernaldez CB., Pacheco VA., Morales ASV., Martin PJR. 
Adult Cystic Fibrosis: A Possible Cause of Bronchiectasis in COPD Patients 
Archivos de Bronconeumología 2019; 55: 163 - 164

Castner LM., Nast SZ., Arteta M. 
Progressive Scoliosis in a Child with Cystic Fibrosis 
Case Reports in Pediatrics 2019; : ArNo: 1471879

Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis 
Science Translational Medicine 2019; 11: 486.eea4388

A glycopolymer improves vasocoelasticity and mucociliary transport of abnormal cystic fibrosis mucus 
JCI Insight 2019; 7: 4:e13362

Gold LS., Patrick DL., Hansen RN., Beckett V., Goss CH., Kessler L. 
Correspondence between symptoms and preference-based health status measures in the STOP study 
Journal of Cystic Fibrosis 2019; 18: 251 - 264

Impact of high- versus low-risk genotype on sinonasal radiographic disease in cystic fibrosis 
Laryngoscope 2019; 129: 788 - 793
Hernandez R., Delpiano L., Amador J., Arias M., Delgado JC.
Neuropenia associated with the use of cefepime in pediatric patients with cystic fibrosis
*Revista Chilena de Infectologia* 2019; 36: 112 - 114

Khalaf RT., Green D., Amankwah EK., Peck J., Carr V., Goldenberg NA., Wilsey M.
Percutaneous Endoscopic Gastrostomy Tubes May Be Associated With Preservation of Lung Function in Patients With Cystic Fibrosis
*Nutrition in Clinical Practice* 2019; 34: 290 - 296

Khan MA., Ali ZS., Sweezy N., Grasemann H., Palaniyar N.
Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation
*Genes* 2019; 10: 3:183

Respiratory rate in infants with cystic fibrosis throughout the first year of life and association with lung clearance index measured shortly after birth.
*Journal of Cystic Fibrosis* 2019; 18: 118 - 126

Lombardi E., Gambazza S., Pradal U., Braggion C.
Lung clearance index in subjects with cystic fibrosis in Italy
*Italian Journal of Pediatrics* 2019; 45: ArNo: 56

Matusovsky OS., Kachmar L., Ijpma G., Panariti A., Benedetti A., Martin JG., Lauzon AM.
Contractile Properties of Intrapulmonary Airway Smooth Muscle in Cystic Fibrosis
*American Journal of Respiratory Cell and Molecular Biology* 2019; 60: 434 - 444

McCormack P., Burnham P., Southern KW.
A systematic Cochrane Review of autogenic drainage (AD) for airway clearance in cystic fibrosis
*Paediatric Respiratory Reviews* 2019; 29: 23 - 24

McElvaney OJ., Gunaratnam C., Reeves EP., McElvaney NG.
A specialized method of sputum collection and processing for airway clearance in cystic fibrosis
*A systematic Cochrane Review of autogenic drainage (AD) for airway clearance in cystic fibrosis*

Mirla AA., Robinson TE., Gifford K., Guo HH.
3D Printing and the Cystic Fibrosis Lung
*Journal of Cystic Fibrosis* 2019; 18: 278 - 279

Parazzi PLF., Marson FAL., Ribeiro MAGO., Schivinski CIS., Ribeiro JD.
Correlation between parameters of volumetric capnography and spirometry during a submaximal exercise protocol on a treadmill in patients with cystic fibrosis and healthy controls
*Pulmonology* 2019; 25: 21 - 31

Pecellin ID., Ortega MM., Hernandez I.C., Barrera LM., Zara PM., Valera MJM., Gallego MEQ.
Persistent Atelectasis in a Patient With Cystic Fibrosis: Are Antibiotics Always Needed?
*Archivos de Bronconeumologia* 2019; 55: 54 - 55

Pletcher SD., Goldberg AN., Cope EK.
Loss of Microbial Niche Specificity Between the Upper and Lower Airways in Patients With Cystic Fibrosis
*Laryngoscope* 2019; 129: 544 - 550

Poncin W., Lebecque P.
Lung clearance index in cystic fibrosis
*Revue des Maladies Respiratoires* 2019; 36: 377 - 395

Rafeey M., Moghadham YJ., Rezaeeyan S.
Sinonasal Manifestations in Children with Cystic Fibrosis
*Iranian Journal of Pediatrics* 2019; 29: 1:e66015

Rossi GA., Morelli P., Galietta LJ., Colin AA.
Airway microenvironment alterations and pathogen growth in cystic fibrosis
*Pediatric Pulmonology* 2019; 54: 497 - 506

Schultz A., Marsh JA., Saville BR., Norman R., Middleton PG., Greville HW., Bellgard ML., Berry SM., Snelling T.
Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis
*Frontiers in Pharmacology* 2019; 10: ArNo: 301

Thomas M., Bagg W., Kolbe J.
Infection risks for patients from healthcare workers with cystic fibrosis
*Respirology* 2019; 24: 392 – 393

**Radiology**

Multiprobe Nuclear Imaging of the Cystic Fibrosis Lung as a Biomarker of Therapeutic Effect
*Journal of Aerosol Medicine and Pulmonary Drug Delivery* 2019; 27: 794 - 802

The value of high-resolution computed tomography (HRCT) to determine exercise ventilatory inefficiency and dynamic hyperinflation in adult patients with cystic fibrosis
*Respiratory Research* 2019; 20: ArNo: 78

Robinson P., Morgan L.
Bronchiectasis in PCD looks different to CF on CT scan
*Multidisciplinary Respiratory Medicine* 2018; 13:

Santyr G., Kanhere N., Morgado F., Raymond HJ., Ratjen F., Couch MJ.
Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease
*Academic Radiology* 2019; 26: 344 - 354

Sasihuseyinoglu AS., Altintas DU., Soyupak S., Dogruel D., Yilmaz M., Serbes M., Duyuler G.
Evaluation of high resolution computed tomographic findings of cystic fibrosis
*Korean Journal of Internal Medicine* 2019; 34: 335 - 343

Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group
*Journal of Clinical Immunology* 2019; 39: 45 - 54

Sodhi KS., Gupta P., Shirvastav A., Saxena AK., Mathew JL., Singh M., Agarwal R.
Evaluation of 3 T lung magnetic resonance imaging in children with allergic bronchopulmonary aspergillosis: Pilot study
*European Journal of Radiology* 2019; 111: 88 – 92

Tadd K., Morgan L., Rosenow T., Schultz A., Susanto C., Murray C., Robinson P.
CF derived scoring systems do not fully describe the range of structural changes seen on CT scans in PCD
*Pediatric Pulmonology* 2019; 54: 471 - 477

**Screening**

Dankert-Roelse JE., Bouva MJ., Jakobs BS., Janssens HM., de Winter-de Groot KM., Schonbeck Y., Gille JJP., Gulmans VAM., Verschoof-Puite RK., Schielen PCJ., Verkker PH.
Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands
*Journal of Cystic Fibrosis* 2019; 18: 54 - 63
Tetrahydronobipiperine improves endothelial function in patients with cystic fibrosis
*Journal of Applied Physiology* 2019; 126: 60 - 66

Kelly A., De Leon DD., Sheidt S., Camburn D., Kubrak C., Pelekis AJ., Stefanovski D., Hadjiilidiss D., Rickers MR., Rubenstein C.
Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy
*American Journal of Respiratory and Critical Care Medicine* 2019; 199: 342 - 351

Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor A Cohort Study from the Cystic Fibrosis Registry of Ireland

Li A., Vigers T., Pyle L., Zemanick E., Nadeau K., Sagel SD., Chao CL.
Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
*Journal of Cystic Fibrosis* 2019; 18: 144 - 149

Luan XJ., Tan JS., Belev G., Jagadeeshan S., Murray B., Hassan N., Machen TE., Chapman LD., Ianowski JP.
Nebulized hypertonic saline triggers nervous system-mediated active liquid secretion in cystic fibrosis swine trachea
*Scientific Reports* 2019; 9: ArNo: 540

McCollel SA., Konstan MW., Ramsey BW., Elborn JS., Boyle MP., Wainwright CE., Waltz D., Vera-Llonch M., Marigowda G., Jiang JG., Rubin JL.
Lumacaftor/ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1
*Journal of Cystic Fibrosis* 2019; 18: 94 - 101

McCormick J., Cho DY., Lampkin B., Richman J., Hathorne H., Rowe SM., Woodworth BA.
Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients
*International Forum of Allergy & Rhinology* 2019; 9: 292 - 297

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
*Lancet Respiratory Medicine* 2019; 7: 325 - 335

Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
*Journal of Cystic Fibrosis* 2019; 18: 271 - 277

Newsome SJ., Daniel RM., Carr SB., Bilton D., Keogh RH.
Investigating the effects of long-term dornase alfa use on lung function using registry data
*Journal of Cystic Fibrosis* 2019; 18: 110 - 117

Ong V., Mei V., Cao L., Lee K., Chung EJ.
Nanomedicine for Cystic Fibrosis
*Slas Technology* 2019; 24: 169 - 180

Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine
*Frontiers in Pharmacology* 2019; 10: ArNo: 121

Rey MM., Bonk MP., Hadjiilidiss D.
Cystic Fibrosis: Emerging Understanding and Therapies
*Annual Review of Medicine, Vol 70* 2019; 70: 197 - 210

Sadowska B., Wojcik U., Krzyzanowska-Kowalczyk J., Kowalczyk M., Stochmal A., Rywania J., Burzynska J., Rozalska B.
The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
*Molecules* 2019; 24: 6-1151

Sesma JL., Wu B., Stuhlmueller TJ., Scott DW.
SPX-101 is stable in and retains function after exposure to cystic fibrosis sputum
*Journal of Cystic Fibrosis* 2019; 18: 244 - 250

Shilton M., Krishan A., Patel S., Sinha IP., Southern KW.
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
*Cochrane Database of Systematic Reviews* 2019; : 1:CD009841

van de Peppel IP., Doktorova M., Berkers G., de Jonge HR., Houwen RHJ., Verkade HJ., Jonker JW., Bodewes FAJA.
IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation
*Journal of Cystic Fibrosis* 2019; 18: 286 - 293

van Koningsbruggen-Rietschel S.
Novel treatment modalities for cystic fibrosis
*Pneumologie* 2019; 16: 88 - 97

Warren E., Morgan K., Toward TJ., Schwenkglenks M., Leadbetter J.
Cost Effectiveness of Inhaled Mannitol (Bronchitol(R)) in Patients with Cystic Fibrosis
*Pharmacoconomics* 2019; 37: 435 - 446

Wu HX., Zhu M., Xiong XF., Wei J., Zhou KQ., Cheng DY.
Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis
*Advances in Therapy* 2019; 36: 451 – 461

Transplantation

Klee P., Dirlewanger M., Lavaillard V., Melin VA., Mornand A., Perin N., Petit LM., Soccal PM., Wildhaber BE., Zumsteg U., Blouin JL., Berney T., Schwitzgebel VM.
Combined Pancreatic Islet-Lung-Liver Transplantation in a Pediatric Patient with Cystic Fibrosis-Related Diabetes
*Hormone Research in Paediatrics* 2018; 90: 270 - 274

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with cefazidime-avibactam
*Infection* 2019; 47: 289 - 292

Luparello P., Lazio MS., Voltolini L., Borch B., Tacchetti G., Maggiore G.
Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis
*European Archives of Oto-Rhino-Laryngology* 2019; 276: 1341 - 1347

Mendogni P., Henchi S., Morlacchi I.C., Tosi D., Nosotti M., Tarzia P., Gregorini AL., Rossol I.
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders in Cystic Fibrosis Lung Transplant Recipients: A Case Series
*Transplantation Proceedings* 2019; 51: 194 - 197

Aminoglycoside exposure and renal function before lung transplantation in adult cystic fibrosis patients
*Nephrology Dialysis Transplantation* 2019; 34: 118 - 122
Cystic Fibrosis: From Qualification to Lung Transplantation, a Single Center Experience  
*Annals of Transplantation* 2019; 24: 185 - 190

Successful lung transplantation for chronic *Mycobacterium abscessus* infection in advanced cystic fibrosis, a case series  
*Transplant Infectious Disease* 2019; 21: e13046

Welsner M., Straburg S., Taube C., Sutharsan S.  
Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T-a case report  
*BMC Pulmonary Medicine* 2019; 19: ArNo: 76